KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Gains from Sales and Divestitures (2019)

Amneal Pharmaceuticals has reported Gains from Sales and Divestitures over the past 1 years, most recently at $479299.0 for Q4 2019.

For Q4 2019, Gains from Sales and Divestitures changed N/A year-over-year to $479299.0; the TTM value through Dec 2019 reached $479299.0, changed N/A, while the annual FY2019 figure was $479299.0, N/A changed from the prior year.
Gains from Sales and Divestitures for Q4 2019 was $479299.0 at Amneal Pharmaceuticals.
Over five years, Gains from Sales and Divestitures peaked at $479299.0 in Q4 2019 and troughed at $479299.0 in Q4 2019.